Dear Doctor Anaplastic lymphoma kinase positive (ALK+) lung cancer is a relatively rare subtype, occurring in about 1 in 25 non-small-cell lung cancer (NSCLC) cases, which itself constitutes approximately 85% of all lung cancer cases worldwide. Promisingly, inhibitors designed for the ALK gene, such as Crizotinib, Alectinib, Brigatinib, and Lorlatinib have demonstrated significant potential in NSCLC treatment.1,2 We would like to hear your thoughts on the current treatment practices and your preferred management approach for NSCLC patients. Here’s a survey on this topic that’ll take only two minutes to fill!
Do share your experience and insights with us. Read more at: https://mariner.docplexus.com/#/app/mposts/cda0604c-1d0c-4cd9-a3b3-0fce87ed6a39 Copyright 2023 © Docplexus